

Substitute for form 1449A/PTO				Application Number	10/715,417
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Filing Date	November 19, 2003
				First Named Inventor	Eivind Per Thor STRATEN et al.
				Art Unit	1646 1644
				Examiner Name	Unassigned Marianne Dibrino/
Sheet	3	of	10	Attorney Docket Number	60820.000004

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	TRANSLATION	
			YES	NO
MD	18.	ANDERSEN, M. H. et al., "Phosphorylated Peptides Can Be Transported by TAP Molecules, Presented by Class I MHC Molecules, and Recognized by Phosphopeptide-Specific CTL." J. Immunol., 163:3812-3188, 1999	—	—
	19.	MCCUTCHEON, M. et al., "A sensitive ELISPOT assay to detect low-frequency human T lymphocytes," J. Immunol. Methods, 210:149-166, 1997	—	—
	20.	PASS, H. A. et al., "Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay." Cancer J. Sci. Am., 4: 316-323, 1998	—	—
	21.	BERKE, Z. et al., "Peptides spanning the junctional region of both the abl/bcr and the bcr/abl fusion proteins bind common HLA class I molecules," Leukemia, 14:419-426, 2000	—	—
	22.	FALK, K. et al., "Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules," Nature, 351:290-296, 1991	—	—
	23.	CORNELISON, T. L., "Human papillomavirus genotype 16 vaccines for cervical cancer prophylaxis and treatment, Curr. Opin. Oncol., 12:466-473, 2000	—	—
	24.	LEE, S. P. et al., "CTL control of EVB in nasopharyngeal carcinoma (NPC): EBV-specific CTL responses in the blood and tumors of NPC patients and the antigen-processing function of the tumor cells," Immunol., 165: 573-582, 2000	—	—
	25.	SWANA, H. S. et al., "Tumor content of the antiapoptosis molecule survivin and recurrence of bladder cancer. N. Engl. J. Med., 341: 452-453, 1999	—	—
MD	26.	SALGALLER, M. L. et al., "Recognition of multiple epitopes in the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated in vitro with synthetic peptides. Cancer Res., 55: 4972-4979, 1995	—	—

EXAMINER SIGNATURE /Marianne Dibrino/ DATE CONSIDERED 03/12/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEP 25 2009

PTO/SB/08B (08/03) (modified)

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

U.S. PATENT & TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

Application Number	10/715,417
Filing Date	November 19, 2003
First Named Inventor	Eivind Per Thor STRATEN <i>et al.</i>
Art Unit	1644
Examiner Name	Marianne DIBRINO, Ph.D.
Attorney Docket Number	60820.000004

U.S. PATENT DOCUMENTS

*Examiner Initials	Cite No.	DOCUMENT NUMBER Number - Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
--------------------	----------	--	--------------------------------	--	---

FOREIGN PATENT DOCUMENTS

*Examiner Initials	Cite No.	FOREIGN PATENT DOCUMENT	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	TRANSLATION	
		Country Code Number-Kind Code (if known)				YES	NO
	1.	WO	2005/049073	06-02-2005	STRATEN et al.	<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS - NON-PATENT LITERATURE DOCUMENTS

*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	TRANSLATION	
			YES	NO
	2.	BERGER et al. Int. J. Cancer, 2004, 111: pages 229-237	<input type="checkbox"/>	<input type="checkbox"/>
	3.	BODEY et al. Anticancer Research 2000, 20: pages 2665-2676	<input type="checkbox"/>	<input type="checkbox"/>
	4.	BOON et al. Ann. Rev. Immunol. 2006, 24: pages 175-208	<input type="checkbox"/>	<input type="checkbox"/>
	5.	CAMPOLI et al., Vaccine. 2002;20, A40-5	<input type="checkbox"/>	<input type="checkbox"/>
	6.	CHAUX et al. J. Immunol. 1999, 163: pages 2928-2936.	<input type="checkbox"/>	<input type="checkbox"/>
	7.	Database EMBL. Baculoviral IAP repeat-containing protein 5 (apoptosis inhibitor survivin) (apoptosis inhibitor 4) (TIAP) 30 May 2000. XP002392545, retrieved from EBI, Database accession no. 070201 May	<input type="checkbox"/>	<input type="checkbox"/>

EXAMINER SIGNATURE

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

~~ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH.~~ /M.D./